LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

Search

Novocure Ltd

Closed

SectorHealthcare

14.25 -19.99

Overview

Share price change

24h

Current

Min

14.08

Max

14.44

Key metrics

By Trading Economics

Income

-47M

-71M

Sales

-295K

174M

EPS

-0.62

Profit margin

-40.871

Employees

1,605

EBITDA

-29M

-63M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+43.42% upside

Dividends

By Acuity

Next Earnings

23 lip 2026

Market Stats

By TradingEconomics

Market Cap

593M

2B

Previous open

34.24

Previous close

14.25

News Sentiment

By Acuity

59%

41%

261 / 342 Ranking in Healthcare

Novocure Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat